Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Paresthesia 1Neurotoxicity Syndromes 1Neoplasms 1Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Breast Diseases 1

Interventions

Oxaliplatin 4Sodium Chloride 3Paclitaxel 3Carboplatin 3xaliproden 2Taxes 2Radiotherapy, Intensity-Modulated 2Radiotherapy, Conformal 2Magnesium Sulfate 2Leucovorin 2Fluorouracil 2Calcium Gluconate 2neurotropin 1glutamic acid diethyl ester 1Vitamin E 1Thioctic Acid 1Temozolomide 1Saline Solution 1Radiosurgery 1Prednisolone 1Methylprednisolone 1Memantine 1Lamotrigine 1Ketamine 1Glutathione 1Glutamic Acid 1Ginkgo Extract 1Gabapentin 1Duloxetine Hydrochloride 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neurotoxicity Syndromes × 2,2'-dithiodiethanesulfonic acid × Clear all
NCT00039780 2022-07-13

Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel

BioNumerik Pharmaceuticals, Inc.

Phase 3 Completed
764 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Paresthesia, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡